Get the Stockscreener App
5.65
0.53%
0.03
Bioharvest Sciences Inc stock is traded at $5.65, with a volume of 5,547.
It is up +0.53% in the last 24 hours and down -4.88% over the past month.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
See More
Previous Close:
$5.62
Open:
$5.7
24h Volume:
5,547
Relative Volume:
0.35
Market Cap:
$102.23M
Revenue:
$22.43M
Net Income/Loss:
$-17.19M
P/E Ratio:
-4.252
EPS:
-1.3288
Net Cash Flow:
$-10.02M
1W Performance:
+1.80%
1M Performance:
-4.88%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.65
$5.80
1-Week Range:
$5.40
$6.10
52-Week Range:
$4.7237
$6.89
Bioharvest Sciences Inc Stock (BHST) Company Profile
Name
Bioharvest Sciences Inc
Sector
Industry
Phone
-
Address
-
Compare BHST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHST
Bioharvest Sciences Inc
|
5.65 | 102.23M | 22.43M | -17.19M | -10.02M | -1.3288 |
|
KHC
Kraft Heinz Co
|
29.46 | 35.56B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
57.51 | 32.31B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.37 | 28.46B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
75.32 | 20.81B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.58 | 16.80B | 11.92B | 805.04M | 1.01B | 1.46 |
Bioharvest Sciences Inc Stock (BHST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Maxim Group | Buy |
Bioharvest Sciences Inc Stock (BHST) Latest News
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock? - MSN
Research Analysts Set Expectations for BHST Q2 Earnings - The AM Reporter
Analysts Set Expectations for BHST Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for BHST Q2 Earnings? - Defense World
H.C. Wainwright maintains BioHarvest stock Buy rating, $14 target - Investing.com Australia
H.C. Wainwright maintains BioHarvest stock Buy rating, $14 target By Investing.com - Investing.com Canada
BioHarvest Sciences’ (BHST) Buy Rating Reaffirmed at HC Wainwright - Defense World
Here's Why BioHarvest Sciences (NASDAQ:BHST) Can Afford Some Debt - simplywall.st
Q1 Earnings Forecast for BHST Issued By Diamond Equity - Defense World
BioHarvest Sciences Reports Strong Revenue Growth and Strategic Expansion - TipRanks
BioHarvest Sciences Reports Strong Growth Amid Challenges - TipRanks
BioHarvest CEO talks Nasdaq uplisting, profit targetsICYMI - Proactive financial news
BioHarvest Sciences Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones - Proactive financial news
Small cap wrap: Ideal Power, Voyageur Pharmaceuticals, North Bay Resources, Trust Stamp... - Proactive financial news
BioHarvest shares rise after Q4 results show strong demand for VINIA products - Proactive financial news
BioHarvest Sciences Inc (BHST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo
BioHarvest Sciences Inc (BHST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates - MSN
BioHarvest Sciences Reports Strong Financial Growth and Strategic Partnership - TipRanks
BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results - Newsfile
Contrasting CureVac (NASDAQ:CVAC) & BioHarvest Sciences (NASDAQ:BHST) - The AM Reporter
BioHarvest Sciences (BHST) to Release Earnings on Monday - Defense World
Ilan Sobel, CEO of BioHarvest Sciences - iHeart
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength? - Nasdaq
BioHarvest Sciences to Announce Q4 and Full Year 2024 Financial Results - TipRanks
BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.m. Eastern Time - Newsfile
BIOHARVEST SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025 - Newsfile
BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound - Proactive Investors USA
BioHarvest’s Olive Cell Compound Shows Promise in Tackling Liver Fat Accumulation - TipRanks
BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells - Newsfile
EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells - Benzinga
BioHarvest Sciences Inc. (NASDAQ:BHST) Not Flying Under The Radar - Simply Wall St
BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD - Newsfile
BioHarvest Sciences Inc.'s (NASDAQ:BHST) Shift From Loss To Profit - Yahoo Finance
BioHarvest Sciences surpasses 50 million dollars in VINIA sales, plans major production expansion - Proactive financial news
BioHarvest's VINIA sales top $50M, plans production boost By Investing.com - Investing.com Canada
BioHarvest’s VINIA Achieves $50 Million in Sales, Plans Major Expansion - TipRanks
BioHarvest's VINIA sales top $50M, plans production boost - Investing.com India
BioHarvest’s VINIA sales top $50M, plans production boost - Investing.com
BioHarvest’s VINIA sales top $50M, plans production boost By Investing.com - Investing.com Nigeria
BioHarvest Sciences to Delist from CSE, Focuses on Nasdaq - TipRanks
Bioharvest Sciences Inc Stock (BHST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):